Newsletter to Shareholders from CEO, Max C. Li UpdatedProgress ReportFollowing Meetingswith the T-Mobile USA DearShareholders, September 18, 2019I have exciting and groundbreaking news for you! I am presently at T-Mobile USA’s headquarters in Bellevue, Washington state, meeting with the T-Mobile B2B sales team and the T-Mobile USA service activation team. After several months of careful review by T-Mobile USA, I am proud to advise that Tri Cascadehas been selected as T-Mobile’s authorized NB IoTService Provider as well as being selected as their authorized Wholesale NB IoT Connectivity and Product Integration Provider to their primary business partners and customers! This changes everything for us going forward and will solidifyour close business relationship with T-Mobile USAthrough the establishment ofa formal Service Provider Agreement betweenT-Mobile USA and Tri Cascade,Inc.! Thisopens the door to numerous possibilities and potential revenue opportunities for ourfuture.I will provide a further update on our T-Mobile USA status upon my return to our Newport Beach office. So, please stay tuned valued Shareholders for additional exciting newsin this regard!Respectfully,Max C. Li.CEOAbout Tri Cascade, Inc and Saddle Ranch Media, Inc.With operations both in the United States and in Taiwan, Saddle Ranch Media’s wholly-owned subsidiaryTriCascade,Inc.www.TriCascadeInc.comispositioningitselftobecometheleading innovator,manufacturer,anddistributorofthemostsophisticatedandcompellingSmartCityand Smart House IoT devices to enable our future A.I. lifestyle! The Company’s solutions include the NB IoT Ambient Air Quality Monitor, and the first of its kind “Self-Internet smart thermostat –THERMORING+” with A.I. Voice and Facial Recognition throughout the house by i.VA the Intelligent Voice/Video Assistant. Additionally, “Smart Outlet”, “Smart Dimmer” and many more Smart Home solutions are now emerging from Tri Cascade productdevelopment.Safe Harbor StatementCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differmaterially.Inparticular,thisreleasecontainsforward-lookinginformationrelatingtothedevelopmentof the Corporation’s assets and its business goals and objectives. The forward-looking information containedin this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as requiredbyapplicablesecuritieslaws.Becauseoftherisks,uncertaintiesandassumptionscontainedherein, investorsshouldnotplaceunduerelianceonforwardlooking-information.Theforegoingstatementsexpressly qualify any forward-looking information containedherein.Interviews and Contact: Alan Bailey, 310-722-6624Investor relations:firstname.lastname@example.org
- ← Unitil Energy Pilots Virtual Power Plant in Massachusetts with ReVision Energy and Eguana Technologies
- Vapen MJ Ventures Joins the Stock Day Podcast. (VAPNF) September 19, 2019 →
You May Also Like
This New Device’s Rapid Pathogen Identification May Be Our Next Big Medical Breakthrough (LXXGF) Lexagene Holdings.
Stock Day Media Comments Off on This New Device’s Rapid Pathogen Identification May Be Our Next Big Medical Breakthrough (LXXGF) Lexagene Holdings.
PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19
Stock Day Media Comments Off on PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19
Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7
Stock Day Media Comments Off on Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7